Form 4: Cellectar Biosciences CEO James Caruso Acquires 900,000 Stock Options Following Shareholder Approval

James Caruso, President and CEO of Cellectar Biosciences, acquired 900,000 stock options after shareholder approval of the company's amended 2021 Stock Incentive Plan.

Summary

• James V. Caruso, the President and CEO of Cellectar Biosciences, acquired 900,000 stock options on June 14, 2024.
• The options were granted contingently on December 15, 2023, and were subject to shareholder approval of Cellectar's amended 2021 Stock Incentive Plan.
• Shareholder approval was obtained at Cellectar's 2024 Annual Meeting of Stockholders on June 14, 2024.
• The exercise price of the stock options is $2.65.
• The options vest over a three-year period from December 15, 2023, with one-third vesting on the first anniversary and the remainder vesting in 24 equal monthly installments.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The shareholder approval is a positive sign.

Positives

• The granting of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders. The size and terms of the grant are typical for a company of Cellectar's size and stage of development.

Comparison to Industry Standards

• Stock option grants to CEOs in the biotech industry typically range from 1% to 5% of outstanding shares, depending on the company's size and performance.
• Vesting schedules of three to four years are standard practice to ensure long-term commitment.
• Exercise prices are usually set at or above the current market price of the stock at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the CEO successfully executes the company's strategy.
• The grant incentivizes the CEO to improve company performance, which could benefit employees and other stakeholders.

Key Dates

Keywords

stock options, Cellectar Biosciences, CEO, James Caruso, shareholder approval, stock incentive plan, CLRB, Form 4